MAINSAIL
Registration number(s): 
Summary of trial and patient characteristics
|
Recruitment status
|
Closed (no longer recruiting)
|
|
Trial start date
|
25 Feb 2010
|
|
Trial end date
|
16 Jan 2012
|
|
Sex
|
Male
|
|
Age range
|
18 + years
|
| |
|
Cancer location
|
Prostate
|
|
Stage
|
Metastatic, Recurrent
|
|
Surgery
|
Never, Previously, Currently
|
|
Medical treatment
|
Never, Previously, Currently
|
|
Hormone treatment
|
Previously, Currently
|
|
Chemotherapy
|
Never
|
|
Radiation
|
Never, Previously, Currently
|
|
Scientific title
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or WITHOUT LENALIDOMIDE in Subjects With Castrate-Resistant Prostate Cancer (Other IDs: C-5013-PC-002, EudraCT 2008-007969-23).
Trial summary
The purpose of the study is to determine whether lenalidomide is safe and effective in combination with docetaxel and prednisone for the treatment of subjects with metastatic Castrate-Resistant Prostate Cancer. The addition of lenalidomide to docetaxel and prednisone is proposed to increase the life expectancy of these subjects.
General information about this or other trials
trialslink@cancervic.org.au
Trial sponsor
Celgene Corporation
Participating hospitals
| Hospital | Suburb / Town | Contact name | Email | Phone | Recruitment status |
|
Murray Valley Private Hospital
|
Wodonga
|
Ms Julie Croft
|
jcroft@bordermedonc.com.au
|
02 6051 5325
|
Closed
|
|
Royal Melbourne Hospital, Medical Oncology
|
Parkville
|
Ms Marian Lieschke
|
marian.lieschke@mh.org.au
|
03 9342 7528
|
Closed
|
Print this page
Print this page